Therapeutic Asset Ratings
329 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
bi 3006337
Obesity Disorder
Boehringer Ingelheim
P1
C
(39)
bi 456906
Obesity
Boehringer Ingelheim
P1
C
(39)
DEXKETOPROFEN
Obesity
Kirsehir Ahi Evran Universitesi
P1
C
(39)
Ent-03
Obesity Disorder
Metabolics Pharma
P1
C
(39)
GLUCAGON-LIKE PEPTIDE 1, HUMAN
Obesity Disorder
Indiana University
P1
C
(39)
Glucose-Dependent Insulinotropic Polypeptide
Obesity Disorder
Novo Nordisk A/S
P1
C
(39)
hec88473
Obesity Disorder
Dongguan HEC Biopharmaceutical R&D Co., Ltd.
P1
C
(39)
Insulin Human
Obesity Disorder
Columbia University
P1
C
(39)
METAMIZOLE
Obesity
Kirsehir Ahi Evran Universitesi
P1
C
(39)
Monlunabant
Obesity Disorder
Novo Nordisk A/S
P1
C
(39)
pf-06954522
Obesity Disorder
Pfizer
P1
C
(39)
RIFALDAZINE
Obesity
Vincentage Pharma Co., Ltd
P1
C
(39)
t2026
Obesity Disorder
Sciwind Biosciences APAC CO Pty. Ltd.
P1
C
(39)
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
Obesity Disorder
Duke University
P1
C
(36)
Abbv-295
Obesity Disorder
AbbVie
P1
C
(36)
aciclovir
Obesity Disorder
University Hospital, Toulouse
P1
C
(36)
Aln-6222
Obesity Disorder
Alnylam Pharmaceuticals
P1
C
(36)
azd1043
Obesity Disorder
AstraZeneca
P1
C
(36)
Bmf-650
Obesity Disorder
Biomea Fusion Inc.
P1
C
(36)
Brenipatide
Obesity Disorder
Eli Lilly and Company
P1
C
(36)
da-1726
Obesity Disorder
NeuroBo Pharmaceuticals Inc.
P1
C
(36)
DEXTROSE SOLUTION
Obesity Disorder
Columbia University
P1
C
(36)
Firategrast
Obesity
Boehringer Ingelheim
P1
C
(36)
Follicle Stimulating Hormone
Obesity Disorder
University of Colorado, Denver
P1
C
(36)
hm17321
Obesity Disorder
Hanmi Pharmaceutical Company Limited
P1
C
(36)
Showing 226 to 250 of 329 assets
Previous
Page 10 of 14
Next